Biological Monitoring of HER-2 Positive Patients Using Serum HER-2 and Circulating Tumor Cells
Abstract
Evaluate the feasibility of detecting CTCs by CK19 mRNA in patients with HER-2 positive metastatic breast cancer and correlate this with serum HER-2 and clinical response to Herceptin therapy. Patients/Methods: Blood samples were collected from 55 women with HER-2 positive (lHC+++ and/or FlSH+) metastatic breast cancer and 30 healthy female volunteers Blood samples were collected at baseline, during With the first cycle of H&N at weeks 2, 3 and 5, and at each restaging. Peripheral blood mononuclear cells were isolated and enriched for epithelial cells by immunomagnetic selection. Plasma was used to measure shed HER-2 extracellular domain using as commercially available kit. The presence of CKI 9- gene mRNA was determined by RT%PCR using the LCx probe system (Abbott). Thirty healthy donor blood samples were accessed as controls.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2002
- Accession Number
- ADA411440
Entities
People
- Cinara Dias
- Lyndsay Harris
- Marcia V. Fournier
Organizations
- Dana–Farber Cancer Institute